[{"data": {"name": "Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?", "@type": "ScholarlyArticle", "genre": "report", "author": [{"name": "Mark Trusheim", "@type": "Person"}, {"name": "Murray Aitken", "@type": "Person"}, {"name": "Ernst Berndt", "@type": "Person"}], "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://doi.org/10.3386/w16014", "encodingFormat": "application/pdf"}, {"@type": "MediaObject", "contentUrl": "http://www.nber.org/papers/w16014.pdf", "encodingFormat": "application/pdf"}], "publisher": {"name": "National Bureau of Economic Research", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.3386/w16014", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCe28wnNsSukV-CTKTKSrvA7g2r-CD23CVEAHzUSe-CR5j3kNNjZGzE", "propertyID": "ISCC"}], "datePublished": "2010-05-01"}, "schema": "schema.org", "mediatype": "application/ld+json"}]